Sonoma Pharmaceuticals (SNOA) Income towards Parent Company (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Income towards Parent Company of -$581000.0 for Q1 2026, up 25.13% year-over-year from -$464321.3 in Q1 2025, and up 29.06% quarter-over-quarter from -$819000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Income towards Parent Company (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$581000.0 for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 25.13% year-over-year to -$581000.0; the TTM figure through Mar 2026 stood at -$3.2 million (up 8.16% YoY), while the FY2026 annual figure was -$3.2 million, up 8.16% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$581000.0, up from -$819000.0 in the prior quarter.
- The five-year high for Income towards Parent Company was -$534000.0 in Q3 2025, with the low at -$1.9 million in Q4 2022.
- The 5-year median for Income towards Parent Company is -$972500.0 (2022), against an average of -$1.0 million.
- The sharpest annual moves came in 2023 and 2024: Income towards Parent Company slumped 59.86% in 2023, then soared 58.89% in 2024.
- Sonoma Pharmaceuticals' Income towards Parent Company stood at -$1.9 million in 2022, then soared by 55.34% to -$866000.0 in 2023, then retreated by 7.16% to -$928000.0 in 2024, then grew by 11.75% to -$819000.0 in 2025, then increased by 29.06% to -$581000.0 in 2026.
- Business Quant data shows SNOA's Income towards Parent Company at -$581000.0 in Q1 2026, -$819000.0 in Q4 2025, and -$534000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Sonoma Pharmaceuticals | 5.15 Mn | -184,359.87 | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -330,000.00 |
| Mar 31, 2026 | -581,000.00 |
| Dec 31, 2025 | -819,000.00 |
| Sep 30, 2025 | -534,000.00 |
| Jun 30, 2025 | -1.24 Mn |
| Mar 31, 2025 | -776,000.00 |
| Dec 31, 2024 | -928,000.00 |
| Sep 30, 2024 | -610,000.00 |
| Jun 30, 2024 | -1.14 Mn |
| Mar 31, 2024 | -1.07 Mn |
| Dec 31, 2023 | -866,000.00 |
| Sep 30, 2023 | -1.48 Mn |
| Jun 30, 2023 | -1.42 Mn |
| Mar 31, 2023 | -1.31 Mn |
| Dec 31, 2022 | -1.94 Mn |
| Sep 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -887,000.00 |
| Mar 31, 2021 | -228,000.00 |
| Dec 31, 2020 | -24,000.00 |
| Sep 30, 2020 | -31,000.00 |